Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dopamine beta hydroxylase

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5 result(s) found for: Dopamine beta hydroxylase. Displaying page 1 of 1.
    EudraCT Number: 2008-002855-26 Sponsor Protocol Number: Droxidopa-301 Start Date*: 2008-10-01
    Sponsor Name:Chelsea Therapeutics Inc
    Full Title: A Multi-Centre, Double-Blind, Placebo-Controlled, Parallel-Group Induction-Design Study to assess the Clinical Effect of Droxidopa in Subjects with Primary Autonomic Failure, Dopamine Beta Hydroxyl...
    Medical condition: Symptomatic neurogenic orthostatic hypotension (NOH) in patients with Primary Autonomic Failure (Pharmacodynamic, MSA and PAF), DBH deficiency and Non-Diabetic Neuropathy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-007105-36 Sponsor Protocol Number: Droxidopa-304 Start Date*: 2009-06-03
    Sponsor Name:Chelsea Therapeutics Inc.
    Full Title: A Multi-Centre, One Year Open-Label Study to Assess the Long-Term Safety of Droxidopa in Subjects with Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and...
    Medical condition: Symptomatic neurogenic orthostatic hypotension (NOH) in patients with Primary Autonomic Failure (PD, MSA and PAF), Dopamine Beta Hydroxylase deficiency and Non-Diabetic Neuropathy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005701-22 Sponsor Protocol Number: Droxidopa-303 Start Date*: 2009-04-13
    Sponsor Name:Chelsea Therapeutics Inc
    Full Title: A MULTI-CENTER, OPEN-LABEL STUDY, WITH A TWO WEEK RANDOMIZED, PLACEBO-CONTROLLED, WITHDRAWAL PERIOD, TO ASSESS THE LONG-TERM SAFETY AND CLINICAL BENEFIT OF DROXIDOPA IN SUBJECTS WITH PRIMARY AUTONO...
    Medical condition: Symptomatic neurogenic orthostatic hypotension (NOH) in patients with Primary Autonomic Failure (PD, MSA and PAF), DBH deficiency and Non-Diabetic Neuropathy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-005673-60 Sponsor Protocol Number: Droxidopa-302 Start Date*: 2009-04-22
    Sponsor Name:Chelsea Therapeutics Inc
    Full Title: A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP WITHDRAWAL-DESIGN STUDY TO ASSESS THE CLINICAL EFFECT OF DROXIDOPA IN SUBJECTS WITH PRIMARY AUTONOMIC FAILURE, DOPAMINE ...
    Medical condition: Symptomatic neurogenic orthostatic hypotension (NOH) in patients with Primary Autonomic Failure (PD, MSA and PAF), DBH deficiency and Non-Diabetic Neuropathy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-005118-36 Sponsor Protocol Number: NOH401 Start Date*: 2014-06-30
    Sponsor Name:Chelsea Therapeutics, Incorporated
    Full Title: A clinical study of Patients with symptomatic neurogenic orthostatic HypOtENsion to assess sustaIned effects of droXidopa therapy
    Medical condition: Symptomatic neurogenic orthostatic hypotension
    Disease: Version SOC Term Classification Code Term Level
    17.0 10047065 - Vascular disorders 10031127 Orthostatic hypotension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 20:19:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA